Clinical trial
Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00003646 · Vical, Industry · Completed
Key facts
| NCT number | NCT00003646 |
|---|---|
| Title | Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma |
| Official title | Phase II Study of Allovectin-7 as an Immunotherapeutic Agent in Patients With Stages III and IV Melanoma |
| Lead sponsor | Vical, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma |
| Intervention type | Drug |
| Interventions | allovectin-7 |
| Enrollment | 78 |
| Start date | Aug 1, 1998 |
| Primary completion | Mar 1, 2002 |
| Completion | May 1, 2002 |
| First posted | May 3, 2004 |
| Last update posted | Jul 7, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: